美通社消息,以 AI+机器人驱动新药与新材料研发的创新平台晶泰科技与专注于内分泌领域的创新药企维升药业(VISEN Pharmaceuticals)共同宣布达成项目协议及长期战略合作,本次合作整体规模达数千万元,围绕研发阶段目标,结合关键里程碑有序推进。双方将整合晶泰科技的AI+机器人药物研发平台与维升药业的内分泌领域专业洞见,聚焦维升选择的内分泌代谢领域高临床价值适应症与创新靶点,共同推进创新...
Source Link美通社消息,以 AI+机器人驱动新药与新材料研发的创新平台晶泰科技与专注于内分泌领域的创新药企维升药业(VISEN Pharmaceuticals)共同宣布达成项目协议及长期战略合作,本次合作整体规模达数千万元,围绕研发阶段目标,结合关键里程碑有序推进。双方将整合晶泰科技的AI+机器人药物研发平台与维升药业的内分泌领域专业洞见,聚焦维升选择的内分泌代谢领域高临床价值适应症与创新靶点,共同推进创新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.